Skip to main content
    E

    Elanco Animal Health (ELAN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $25.86
    -0.55 (-2.08%)

    Market Cap: $13.20B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Elanco Animal Health (ELAN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Elanco Animal Health (ELAN) has a market cap of $13.20B and an enterprise value of $16.44B. Its return on invested capital of 1.58% compares with a 11.58% median across 9 similar companies. Its trailing P/E of 22.7x is above its 5-year median of 16.8x.

    Total Valuation

    Enterprise value is 24.56% above the market cap, as debt exceeds cash.

    Market Cap$13.20B
    Enterprise Value$16.44B
    Latest price (Nov 17, 2026)$25.86

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 6, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.04% in the quarter ended Sep 30, 2026 and grew 0.54% a year over 2 years.

    Shares Outstanding499.70M
    Shares Change (YoY)+0.58%
    Shares Change (QoQ)+0.04%
    Share Count Growth (2Y CAGR)+0.54%

    Valuation Ratios

    Sales and book value multiples are 2.5x and 1.9x. Its year-end P/E ranged from 11.0x to 65.3x from 2019 to 2025.

    P/E Ratio22.7x
    Forward P/E21.7x
    P/S Ratio2.5x
    Forward P/S2.5x
    P/B Ratio1.9x
    P/FCF Ratio31.7x
    P/OCF Ratio21.5x
    PEG Ratio2.2

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 18.9x EBITDA and 39.6x free cash flow.

    EV / Sales3.2x
    EV / EBITDA18.9x
    EV / EBIT100.9x
    EV / FCF39.6x

    Price Statistics

    The stock is up 22.62% over 52 weeks and trades 10.28% above its 50-day average.

    Beta (1Y)1.32
    52-Week Change+22.62%
    1-Month Change+10.09%
    3-Month Change+5.55%
    6-Month Change+30.61%
    5-Year Change-29.87%
    Total Return (1Y)+22.62%
    Total Return (3Y CAGR)+29.81%
    Total Return (5Y CAGR)-4.38%
    Return vs SPY (1Y)+9.34%
    Max Drawdown (1Y)-26.23%
    Max Drawdown (3Y)-56.10%
    Sharpe Ratio (1Y)0.44
    Correlation with SPY (1Y)0.42
    50-Day Average$23.45
    200-Day Average$23.87
    52-Week Range$19.40 to $27.98
    RSI (14 Days)59.1
    Average Volume (20 Days)5.38M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.09x current liabilities, and total debt is 0.56x shareholder equity.

    Current Ratio2.09x
    Quick Ratio1.07x
    Debt / Equity0.56x
    Debt / EBITDA4.33x
    Debt / FCF9.09x
    Interest Coverage0.64x

    Returns and Efficiency

    Return on invested capital is 1.58% over the last 12 months, against a 5-year average of -0.73%.

    Return on Equity (ROE)-2.22%
    Return on Assets (ROA)-1.10%
    Return on Invested Capital (ROIC)1.58%
    Return on Capital Employed (ROCE)1.41%
    ROE (5Y Average)-5.06%
    ROA (5Y Average)-2.21%
    ROIC (5Y Average)-0.73%
    Asset Turnover0.38x
    Inventory Turnover1.26x
    Receivables Turnover4.65x
    Cash Conversion Cycle301 days

    Scores

    ELAN has an Altman Z-Score of 1.54, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score1.54
    Altman Z ZoneDistress
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $5.15B over the last 12 months is up 12.13% from the 12 months before.

    Revenue$5.15B
    Revenue Growth (YoY)+12.13%
    Gross Profit$2.89B
    Operating Income$140.00M
    Pretax Income-$92.00M
    Net Income-$147.00M
    EBITDA$857.00M
    EBIT$163.00M
    Reported EPS (TTM)$1.14

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 49.70% of the $13.34B in total assets.

    Cash and Equivalents$465.00M
    Total Debt$3.71B
    Net Debt$3.24B
    Net Debt Per Share$6.49
    Working Capital$1.94B
    Shareholder Equity$6.63B
    Book Value Per Share$13.26
    Tangible Book Value-$1.20B
    Total Assets$13.34B
    Total Liabilities$6.71B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $206.00M of capital spending, operating cash flow left $408.00M of free cash flow.

    Operating Cash Flow$614.00M
    Capital Expenditures$206.00M
    Free Cash Flow$408.00M
    FCF Per Share$0.82
    Depreciation and Amortization$694.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 2.72%, against a 5-year average of -4.44%.

    Gross Margin56.18%
    Operating Margin2.72%
    Pretax Margin-1.79%
    Net Margin-2.86%
    EBITDA Margin16.65%
    EBIT Margin3.17%
    FCF Margin7.93%
    Gross Margin (5Y Average)55.61%
    Operating Margin (5Y Average)-4.44%
    Net Margin (5Y Average)-7.42%

    Growth

    Revenue grew 2.25% a year over 3 years, and EPS fell 5.06% a year.

    Revenue Growth (3Y CAGR)+2.25%
    Revenue Growth (5Y CAGR)+7.59%
    EPS Growth (3Y CAGR)-5.06%
    EPS Growth (5Y CAGR)+15.11%
    FCF Growth (3Y CAGR)+0.35%
    Book Value Per Share Growth (2Y CAGR)+2.15%

    Revenue and profit by year

    Dividends and Yields

    ELAN does not pay a dividend. Its free cash flow yield is 3.16%.

    Earnings Yield4.41%
    FCF Yield3.16%
    Shareholder Yield0.00%

    Peer Position

    Against 10 similar companies, ELAN has the 3rd highest P/E.

    P/E Ratio22.7x vs 18.2x median
    P/S Ratio2.5x vs 3.2x median
    ROIC1.58% vs 11.58% median
    Revenue Growth (Trailing 4 Quarters, YoY)+12.13% vs +4.27% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 7.50% and EPS growth at 16.56% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+7.50%
    EPS Growth Forecast (2Y CAGR)+16.56%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ELAN

    What is ELAN's market cap?

    Elanco Animal Health has a market cap of $13.20B. Its enterprise value, which adds debt and subtracts cash, is $16.44B.

    What is ELAN's P/E ratio?

    Elanco Animal Health has a trailing P/E ratio of 22.7x and a forward P/E of 21.7x.

    How many shares of ELAN are outstanding?

    Elanco Animal Health has 499.70M shares outstanding. The count is up 0.58% from a year earlier.

    Does ELAN pay a dividend?

    No. Elanco Animal Health does not pay a dividend.

    How much debt does ELAN have?

    Elanco Animal Health has $3.71B of total debt and $465.00M of cash and equivalents, a net debt position of $3.24B.